FDA Admits It Has Yet To Fill In Big Gaps On Biosimilar Regs
The revelations of slower-than-hoped progress emerged during an FDA advisory committee hearing and were described as resulting from caution on a new pharmaceutical frontier. Agency officials offered few insights as to when clarity would be available.
“There are some things that have not yet been dealt...
To view the full article, register now.